Anne A.
- Country
- Sweden
- Department
- Strålningsvetenskaper, onkologi
Research Overview
- A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
- Evaluation of Triptorelin for Ovarian Reserve Preservation in Young Females Undergoing Chemotherapy for Breast Cancer, Leukemia, Lymphomas, and Sarcomas
- Evaluation of Extended Adjuvant Endocrine Therapy with Tamoxifen, Exemestane, Anastrozole, and Letrozole in High-Risk Luminal Breast Cancer Patients
Data & Insights
Has run more than one trial at 22 of 180 partner sites.
Specializations
Early-Stage Breast Cancer
This investigator specializes in the treatment of triple negative breast cancer (TNBC) and HER2-positive breast cancer at early stages, with particular focus on neoadjuvant therapeutic approaches.
- Preoperative Treatment Strategies
- Pathologic Complete Response Assessment
- Molecular Subtype Analysis
Research extends to innovative treatment combinations and response-guided therapeutic approaches for primary breast cancer.
Advanced Breast Cancer Management
The investigator focuses on treating advanced ER-positive/HER2-negative breast cancer and exploring novel therapeutic strategies for hormone receptor-positive disease.
- Endocrine Therapy Optimization
- Treatment Resistance Mechanisms
- Long-term Disease Management
Expertise includes evaluating extended endocrine treatment approaches and novel therapeutic agents.
Supportive Care Research
Investigation of fertility preservation and long-term outcomes in cancer patients, with particular attention to ovarian function preservation during chemotherapy.
- Gonadal Protection Strategies
- Endocrine Function Monitoring
- Quality of Life Outcomes
Studies include assessment of hormone levels and reproductive function in breast cancer survivors.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.